TWI350829B - Purification process - Google Patents

Purification process

Info

Publication number
TWI350829B
TWI350829B TW093125943A TW93125943A TWI350829B TW I350829 B TWI350829 B TW I350829B TW 093125943 A TW093125943 A TW 093125943A TW 93125943 A TW93125943 A TW 93125943A TW I350829 B TWI350829 B TW I350829B
Authority
TW
Taiwan
Prior art keywords
purification process
purification
Prior art date
Application number
TW093125943A
Other languages
English (en)
Other versions
TW200523231A (en
Inventor
Ulrich Beutler
Gerhard Penn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28686596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI350829(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200523231A publication Critical patent/TW200523231A/zh
Application granted granted Critical
Publication of TWI350829B publication Critical patent/TWI350829B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/82Purification; Separation; Stabilisation; Use of additives
    • C07C209/84Purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
TW093125943A 2003-08-29 2004-08-27 Purification process TWI350829B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0320312.2A GB0320312D0 (en) 2003-08-29 2003-08-29 Purification process

Publications (2)

Publication Number Publication Date
TW200523231A TW200523231A (en) 2005-07-16
TWI350829B true TWI350829B (en) 2011-10-21

Family

ID=28686596

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093125943A TWI350829B (en) 2003-08-29 2004-08-27 Purification process

Country Status (25)

Country Link
US (2) US20060076227A1 (zh)
EP (1) EP1694631A2 (zh)
JP (1) JP5208416B2 (zh)
KR (2) KR101233024B1 (zh)
CN (1) CN100491334C (zh)
AR (1) AR045506A1 (zh)
AU (1) AU2004268051B2 (zh)
BR (1) BRPI0413896A (zh)
CA (1) CA2536498C (zh)
EC (1) ECSP066382A (zh)
GB (1) GB0320312D0 (zh)
IL (1) IL173709A (zh)
IS (1) IS8369A (zh)
MA (1) MA28030A1 (zh)
MX (1) MXPA06002348A (zh)
MY (1) MY149357A (zh)
NO (1) NO20061404L (zh)
NZ (1) NZ545445A (zh)
PE (1) PE20050873A1 (zh)
RU (1) RU2367649C2 (zh)
SG (1) SG145782A1 (zh)
TN (1) TNSN06066A1 (zh)
TW (1) TWI350829B (zh)
WO (1) WO2005021483A2 (zh)
ZA (1) ZA200601264B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0503942D0 (en) * 2005-02-25 2005-04-06 Novartis Ag Purification process
EP1900378A1 (en) * 2006-08-31 2008-03-19 Novartis AG Pharmaceutical compositions for the treatment of fungal infections
AU2009288680B2 (en) 2008-09-05 2013-07-04 Teikoku Pharma Usa, Inc. Iontophoretic drug delivery packaging

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2862103D1 (en) * 1977-08-19 1982-11-18 Sandoz Ag Propenyl amines, processes for their production and pharmaceutical compositions containing them
US5132459A (en) * 1979-08-22 1992-07-21 Sandoz Ltd. Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
CY1410A (en) 1979-08-22 1988-04-22 Sandoz Ag Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
CH678527A5 (en) 1989-06-22 1991-09-30 Sandoz Ag Trans(E)-N-(1-naphthyl:methyl)-heptenyl-amine prepn. - by simultaneously converting crude mixt. contg. cis and trans isomers to salt and precipitating trans isomer
JP3116364B2 (ja) 1989-10-02 2000-12-11 萬有製薬株式会社 エンイン誘導体の製造法
NZ280065A (en) * 1995-09-20 1998-04-27 Apotex Inc Preparation of n-alkyl-n-(1-naphthylmethyl)alk-2-en-4-ynylamine derivatives
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE69909848T2 (de) 1999-10-22 2004-04-15 Richter Gedeon Vegyészeti Gyár R.T. Verfahren zur herstellung substituierter allylamin derivative und deren salze
GB2357762B (en) 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
ITMI20010421A1 (it) * 2001-03-01 2002-09-02 Ausimont Spa Membrane porose semipermeabili di fluoropolimeri semicristallini
ITMI20010430A1 (it) * 2001-03-02 2002-09-02 Dinamite Dipharma S P A In For Metodo per la sintesi di terbinafina
KR100459275B1 (ko) * 2001-12-28 2004-12-03 주식회사유한양행 터비나핀 또는 그의 염산염의 제조방법
ITMI20022534A1 (it) * 2002-11-29 2004-05-30 Dinamite Dipharma S P A Procedimento per la preparazione di terbinafina mediante l'uso di platino come catalizzatore.
US20060004230A1 (en) * 2004-06-30 2006-01-05 Joseph Kaspi Process for the preparation of terbinafine and salts thereof

Also Published As

Publication number Publication date
MXPA06002348A (es) 2006-05-22
KR101233024B1 (ko) 2013-02-13
AU2004268051A1 (en) 2005-03-10
TW200523231A (en) 2005-07-16
JP2007504110A (ja) 2007-03-01
KR20060119892A (ko) 2006-11-24
AU2004268051B2 (en) 2009-03-05
TNSN06066A1 (en) 2007-10-03
RU2006109640A (ru) 2007-10-10
ZA200601264B (en) 2007-06-27
AR045506A1 (es) 2005-11-02
US20090216047A1 (en) 2009-08-27
PE20050873A1 (es) 2005-11-21
GB0320312D0 (en) 2003-10-01
IS8369A (is) 2006-03-23
CN1845895A (zh) 2006-10-11
US7985323B2 (en) 2011-07-26
RU2367649C2 (ru) 2009-09-20
MY149357A (en) 2013-08-30
ECSP066382A (es) 2006-09-18
IL173709A0 (en) 2006-07-05
BRPI0413896A (pt) 2006-10-24
IL173709A (en) 2012-02-29
JP5208416B2 (ja) 2013-06-12
NO20061404L (no) 2006-08-25
CA2536498A1 (en) 2005-03-10
SG145782A1 (en) 2008-09-29
WO2005021483A2 (en) 2005-03-10
MA28030A1 (fr) 2006-07-03
CN100491334C (zh) 2009-05-27
EP1694631A2 (en) 2006-08-30
WO2005021483A3 (en) 2005-05-12
US20060076227A1 (en) 2006-04-13
NZ545445A (en) 2010-03-26
KR20120054109A (ko) 2012-05-29
CA2536498C (en) 2012-10-09

Similar Documents

Publication Publication Date Title
EG24449A (en) Purification process
GB0320684D0 (en) Process
GB0306432D0 (en) Process
GB0319503D0 (en) Process
GB0313661D0 (en) Process
GB0316756D0 (en) Process
GB0303659D0 (en) Process
EP1612274A4 (en) PROCESS FOR PURIFYING DIFRUCTOSE-DIANHYDRIDE III
GB0209222D0 (en) Purification process
GB0314739D0 (en) Electrodeionisation process
GB0307259D0 (en) Process
GB0313110D0 (en) Process
TWI350829B (en) Purification process
GB0312451D0 (en) Process
GB0313031D0 (en) Process
GB0321240D0 (en) Process
GB0327179D0 (en) Purification method
GB0300733D0 (en) Process
GB0308672D0 (en) Process
GB0316872D0 (en) Process
GB0314380D0 (en) Purification process
GB0305792D0 (en) Purification Process
GB0314960D0 (en) Process
GB0222219D0 (en) Purification process
GB0216451D0 (en) Purification process

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees